Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ironwood Pharmaceuticals, Inc.    IRWD

Delayed Quote. Delayed  - 08/26 10:00:00 pm
13.63 USD   +0.96%
08/05 IRONWOOD PHARMA : reports 2Q loss
08/04 IRONWOOD PHARMA : Provides Second Quarter 2016 Investor Update
08/01IRONWOOD PHARMA : half-yearly earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector news 
Most relevant news about IRONWOOD PHARMACEUTICALS,
08/05 IRONWOOD PHARMACEUTICALS : reports 2Q loss
08/04 IRONWOOD PHARMACEUTICALS : Provides Second Quarter 2016 Investor Update
08/01IRONWOOD PHARMACEUTICALS, INC. : half-yearly earnings release
07/21 IRONWOOD PHARMACEUTICALS : to Host Second Quarter 2016 Investor Update Call
07/15 Herbalife and Ironwood advance; Infosys and Fairmount drop
06/09 IRONWOOD PHARMACEUTICALS : and Allergan Announce Supplemental New Drug Applicati..
06/06 IRONWOOD PHARMACEUTICALS : to Present at Jefferies 2016 Healthcare Conference
06/03DJASTRAZENECA : Completes US Licensing Pact with Ironwood Pharmaceuticals
06/03 IRONWOOD PHARMACEUTICALS : Closes U.S. Transaction with AstraZeneca for Lesinura..
06/01 IRONWOOD PHARMACEUTICALS : to Present at Goldman Sachs 37th Annual Global Health..
05/18 IRONWOOD PHARMACEUTICALS : to Present at 2016 UBS Global Healthcare Conference
05/17 IRONWOOD PHARMACEUTICALS : to Present Linaclotide Data at Digestive Disease Week..
05/17 IRONWOOD PHARMACEUTICALS : to Present Linaclotide Data at Digestive Disease Week..
05/09 IRONWOOD PHARMACEUTICALS : reports 1Q loss
05/09 IRONWOOD PHARMACEUTICALS : Provides First Quarter 2016 Investor Update
More most relevant news
All news about IRONWOOD PHARMACEUTICALS,
08/11 IRONWOOD PHARMACEUTICALS : Patent Application Titled "Treatments for Disorders U..
08/08 IRONWOOD PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
08/05 IRONWOOD PHARMACEUTICALS : reports 2Q loss
08/04 IRONWOOD PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
08/04 IRONWOOD PHARMACEUTICALS : Provides Second Quarter 2016 Investor Update
08/01IRONWOOD PHARMACEUTICALS, INC. : half-yearly earnings release
07/28 IRONWOOD PHARMACEUTICALS : to Host Second Quarter 2016 Investor Update Call
07/21 IRONWOOD PHARMACEUTICALS : to Host Second Quarter 2016 Investor Update Call
07/15 Herbalife and Ironwood advance; Infosys and Fairmount drop
06/16 IRONWOOD PHARMACEUTICALS : and Allergan Announce Supplemental New Drug Applicati..
More news
Sector news : Biotechnology & Medical Research - NEC
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 4th Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/04 Ironwood Pharmaceuticals (IRWD) Q2 2016 Results - Earnings Call Transcript
08/04 Ironwood Pharmaceuticals misses by $0.01, misses on revenue
08/03 Notable earnings after Thursday?s close
07/28 SYNERGY PHARMACEUTICALS : Attractive Acquisition Target
07/25 European Ad Comm backs Allergan's Truberzi for IBS-D
07/22 What To Do With Your Relypsa Winnings


Advertisement
Financials ($)
Sales 2016 251 M
EBIT 2016 -80,0 M
Net income 2016 -108 M
Debt 2016 143 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 8,47x
EV / Sales 2017 6,28x
Capitalization 1 981 M
More Financials
Chart IRONWOOD PHARMACEUTICALS,
Duration : Period :
Ironwood Pharmaceuticals,  Technical Analysis Chart | IRWD | US46333X1081 | 4-Traders
Full-screen chart
Technical analysis trends IRONWOOD PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 14,2 $
Spread / Average Target 4,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter M. Hecht Chief Executive Officer & Director
Terrance G. McGuire Chairman
Thomas Graney Chief Financial Officer & SVP-Corporate Strategy
Mark G. Currie Chief Scientific Officer & Senior Vice President
Brian M. Cali Senior VP-Preclinical, Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IRONWOOD PHARMACEUTICA..17.60%1 981
INCYTE CORPORATION-25.27%15 236
CELLTRION, INC.--.--%11 367
LONZA GROUP AG14.78%10 130
QUINTILES TRANSNATIONA..10.24%8 968
ALKERMES PLC-43.94%6 744
More Results